166 related articles for article (PubMed ID: 25586421)
21. Neuro-oncology in a nutshell.
Baehring JM
J Neurooncol; 2004 Nov; 70(2):271-2. PubMed ID: 15674485
[No Abstract] [Full Text] [Related]
22. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
23. Quality improvement in neurology: Neuro-oncology quality measurement set.
Jordan JT; Sanders AE; Armstrong T; Asher T; Bennett A; Dunbar E; Mohile N; Nghiemphu PL; Smith TR; Ney DE
Neurology; 2018 Apr; 90(14):652-658. PubMed ID: 29500290
[No Abstract] [Full Text] [Related]
24. Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.
Lukas RV; Amidei C
Tumori; 2014; 100(3):358-62. PubMed ID: 25076251
[TBL] [Abstract][Full Text] [Related]
25. ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics.
Gupta T; Singh VP; Balasubramian A; Menon H; Kurkure PA; Kumar S; Jalali R
Neurol India; 2020; 68(4):769-773. PubMed ID: 32859812
[TBL] [Abstract][Full Text] [Related]
26. Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting.
Lukas RV; Wainwright DA; Laterra JJ
Future Oncol; 2016 Jan; 12(2):143-7. PubMed ID: 26616737
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
Weller M; Le Rhun E; Van den Bent M; Chang SM; Cloughesy TF; Goldbrunner R; Hong YK; Jalali R; Jenkinson MD; Minniti G; Nagane M; Razis E; Roth P; Rudà R; Tabatabai G; Wen PY; Short SC; Preusser M
Neuro Oncol; 2023 Jul; 25(7):1200-1224. PubMed ID: 36843451
[TBL] [Abstract][Full Text] [Related]
28. The position of the neurologist in neuro-oncology.
Grisold W; Heimans JJ; Postma TJ; Grant R; Soffietti R;
Eur J Neurol; 2002 May; 9(3):201-5. PubMed ID: 11985627
[TBL] [Abstract][Full Text] [Related]
29. The role of tumor board conferences in neuro-oncology: a nationwide provider survey.
Snyder J; Schultz L; Walbert T
J Neurooncol; 2017 May; 133(1):1-7. PubMed ID: 28421461
[TBL] [Abstract][Full Text] [Related]
30. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.
Massey PR; Wang R; Prasad V; Bates SE; Fojo T
Oncologist; 2016 Mar; 21(3):261-8. PubMed ID: 26888691
[TBL] [Abstract][Full Text] [Related]
31. Communication in and clinician satisfaction with multidisciplinary team meetings in neuro-oncology.
Field KM; Rosenthal MA; Dimou J; Fleet M; Gibbs P; Drummond K
J Clin Neurosci; 2010 Sep; 17(9):1130-5. PubMed ID: 20570520
[TBL] [Abstract][Full Text] [Related]
32. The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.
Raman S; Moraes FY; Mendez LC; Taunk NK; Suh JH; Souhami L; Slotman B; Kongkham P; Spratt DE; Berlin A; Marta GN
J Neurooncol; 2018 Aug; 139(1):195-203. PubMed ID: 29869023
[TBL] [Abstract][Full Text] [Related]
33. Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part II: nonspinal tumors.
Lo SS; Chang EL; Ryu S; Chung H; Slotman BJ; Teh BS; Sahgal A
Future Oncol; 2013 Sep; 9(9):1303-6. PubMed ID: 23980677
[TBL] [Abstract][Full Text] [Related]
34. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.
Rahman R; Polley MC; Alder L; Brastianos PK; Anders CK; Tawbi HA; Mehta M; Wen PY; Geyer S; de Groot J; Zadeh G; Piantadosi S; Galanis E; Khasraw M
Lancet Oncol; 2023 Apr; 24(4):e161-e171. PubMed ID: 36990614
[TBL] [Abstract][Full Text] [Related]
35. Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part I: spinal tumors.
Lo SS; Chang EL; Ryu S; Chung H; Slotman BJ; Teh BS; Sahgal A
Future Oncol; 2013 Sep; 9(9):1299-302. PubMed ID: 23980676
[TBL] [Abstract][Full Text] [Related]
36. Publication rate of paper and podium presentations from the European Section of the Cervical Spine Research Society Annual Meeting.
Janssen T; Bartels R; Lind B; Villas Tome C; Vleggeert-Lankamp CL
Eur Spine J; 2016 Jul; 25(7):2311-6. PubMed ID: 26869079
[TBL] [Abstract][Full Text] [Related]
37. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.
Chukwueke UN; Wen PY
CNS Oncol; 2019 Mar; 8(1):CNS28. PubMed ID: 30806082
[No Abstract] [Full Text] [Related]
38. Guidelines in the management of CNS tumors.
Redjal N; Venteicher AS; Dang D; Sloan A; Kessler RA; Baron RR; Hadjipanayis CG; Chen CC; Ziu M; Olson JJ; Nahed BV
J Neurooncol; 2021 Feb; 151(3):345-359. PubMed ID: 33611702
[TBL] [Abstract][Full Text] [Related]
39. Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting and the 5th Annual COGNO (Cooperative Trials Group for Neuro-Oncology) Annual Scientific Meeting. August 8-10, 2012. Brisbane, Queensland, Australia.
Asia Pac J Clin Oncol; 2012 Aug; 8 Suppl 2():40-68. PubMed ID: 22870520
[No Abstract] [Full Text] [Related]
40. Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.
Galanis E; Nassiri F; Coy S; Nejad R; Zadeh G; Santagata S
Am Soc Clin Oncol Educ Book; 2018 May; 38():148-157. PubMed ID: 30231374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
